Human Hyaluronan-binding protein 2(HABP2) ELISA kit

Code CSB-EL010113HU
Size 96T,5×96T,10×96T
Trial Size 24T ELISA Kit Trial Size (Only USD$150/ kit)
* The sample kit cost can be deducted from your subsequent orders of 96T full size kits of the same analyte at 1/5 per kit, until depleted in 6 months. Apply now
Have Questions? Leave a Message or Start an on-line Chat

Product Details

Target Name
hyaluronan binding protein 2
Alternative Names
Factor seven activating protease ELISA Kit; Factor seven-activating protease ELISA Kit; Factor VII activating protein ELISA Kit; Factor VII-activating protease ELISA Kit; FSAP ELISA Kit; HABP 2 ELISA Kit; HABP ELISA Kit; Habp2 ELISA Kit; HABP2_HUMAN ELISA Kit; Hepatocyte growth factor activator like protein ELISA Kit; Hepatocyte growth factor activator-like protein ELISA Kit; HGFAL ELISA Kit; Hyaluronan binding protein 2 ELISA Kit; Hyaluronan-binding protein 2 27 kDa light chain alternate form ELISA Kit; Hyaluronic acid binding protein 2 ELISA Kit; PHBP ELISA Kit; Plasma hyaluronan binding protein ELISA Kit; Plasma hyaluronan-binding protein ELISA Kit
Uniprot No.
Homo sapiens (Human)
Sample Types
serum, plasma, tissue homogenates
Detection Range
0.312 ng/mL-20 ng/mL
0.078 ng/mL
Assay Time
Sample Volume
Detection Wavelength
450 nm
Research Area
Assay Principle
Intra-assay Precision (Precision within an assay): CV%<8%      
Three samples of known concentration were tested twenty times on one plate to assess.  
Inter-assay Precision (Precision between assays): CV%<10%      
Three samples of known concentration were tested in twenty assays to assess.    
To assess the linearity of the assay, samples were spiked with high concentrations of human HABP2 in various matrices and diluted with the Sample Diluent to produce samples with values within the dynamic range of the assay.
  Sample Serum(n=4)  
1:20 Average % 88  
Range % 82-96  
1:40 Average % 89  
Range % 85-95  
1:80 Average % 96  
Range % 91-101  
1:160 Average % 100  
Range % 97-103  
The recovery of human HABP2 spiked to levels throughout the range of the assay in various matrices was evaluated. Samples were diluted prior to assay as directed in the Sample Preparation section.
Sample Type Average % Recovery Range  
Serum (n=5) 103 99-105  
EDTA plasma (n=4) 92 85-98  
Typical Data
These standard curves are provided for demonstration only. A standard curve should be generated for each set of samples assayed.
ng/ml OD1 OD2 Average Corrected  
20 2.875 2.775 2.825 2.725  
10 2.524 2.345 2.435 2.335  
5 1.818 1.787 1.803 1.703  
2.5 0.964 0.901 0.933 0.833  
1.25 0.602 0.586 0.594 0.494  
0.625 0.400 0.425 0.413 0.313  
0.312 0.205 0.195 0.200 0.100  
0 0.101 0.098 0.100    
and FAQs
Store at 2-8°C. Please refer to protocol.
Lead Time
3-5 working days after you place the order, and it takes another 3-5 days for delivery via DHL or FedEx

The human HABP2 ELISA Kit is engineered for accurate measurement of human HABP2 levels from samples including serum, plasma, or tissue homogenates. It uses the Sandwich-ELISA mechanism in combination with the enzyme-substrate chromogenic reaction to measure the human HABP2 content in the sample. The color intensity is positively correlated with HABP2 content in the sample. This kit has been validated against standards of sensitivity, specificity, precision, linearity, recovery, and lot-to-lot consistency.

HABP2, also called FSAP, is an extracellular serine protease involved in the extrinsic pathway of blood coagulation via activation of factor VII and fibrinolysis via activation of pro-urokinase type plasminogen activator (pro-uPA). It negatively regulates vascular integrity via activation of PAR receptor/RhoA/ROCK signaling. It has been implicated in several disease processes including atherosclerosis and deep venous thrombosis. Upregulation of HABP2 has been found in the pulmonary vasculature with acute lung injury (ALI) and promotes disruption of vascular integrity.

Customer Reviews and Q&A

 Customer Reviews

There are currently no reviews for this product.

Submit a Review here

Target Background

(From Uniprot)
Cleaves the alpha-chain at multiple sites and the beta-chain between 'Lys-53' and 'Lys-54' but not the gamma-chain of fibrinogen and therefore does not initiate the formation of the fibrin clot and does not cause the fibrinolysis directly. It does not cleave (activate) prothrombin and plasminogen but converts the inactive single chain urinary plasminogen activator (pro-urokinase) to the active two chain form. Activates coagulation factor VII. May function as a tumor suppressor negatively regulating cell proliferation and cell migration.
Gene References into Functions
  1. The presence of the noninheritable V600E BRAF mutation in this family supports Knudson's "double-hit" hypothesis for cancer development and suggests the involvement of more than 1 gene in the clinical expression of familial nonmedullary thyroid carcinoma. PMID: 29895015
  2. The MI-SNP and MII-SNP FSAP gene polymorphisms were not predictive or prognostic biomarkers for coronary artery diseaseor its main risk factors. PMID: 29927903
  3. NETs bind to FSAP, but do not activate pro-FSAP unless histones are released from NETs by DNAse. This activation of FSAP is likely to be important in diminishing the cytotoxic effect of histones, thus limiting the damaging effect of NETosis. PMID: 29178989
  4. Regulation of gene expression by FSAP in vascular smooth muscle/endothelial cells accounts for its vasculo-regulatory properties. PMID: 28881271
  5. The extent of CAC in women is positively associated with total FSAP, but negatively associated with the specific activity of FSAP suggesting that FSAP may play a role in the evolution of CVD in women. PMID: 28548975
  6. Report peptide substrates used in determining substrate specificity of Factor VII activating protease. PMID: 28726978
  7. Two of 20 probands from families with history of PTC and breast carcinoma (BC) were evaluated by whole exome sequencing (WES) revealing HABP2 p.G534E. PMID: 28402931
  8. No significant association was found between rs11196288 and early-onset ischemic stroke, large artery atherosclerotic stroke, or small vessel disease stroke. rs11196288 presented significant effect on late-onset SVD stroke susceptibility in the older population. PMID: 28501930
  9. study on a wide series of familial non-medullary thyroid cancers indicates that the HABP2(G534E) variant is frequent, but does not segregate with the disease PMID: 28222214
  10. Letter: G534E variant in HABP2 is not associated with non-medullary thyroid cancer in the Spanish population. PMID: 27245704
  11. mutations were not found in familial non-medullary thyroid cancer, and the G534E variant is not the underlying genetic defect in a large sample of sporadic non-medullary thyroid cancer from the Middle East. PMID: 26906432
  12. Study showed that lower FSAP antigen plasma levels were associated with a higher chance of arterial recanalization after tissue plasminogen activator treatment, suggesting an involvement of FSAP in tissue plasminogen activator-induced clot lysis. FSAP antigen determination might be useful in predicting tissue plasminogen activator response in stroke patients. PMID: 27073188
  13. HABP2 polymorphisms are not associated with thyroid cancer. PMID: 27873212
  14. the promoter activity, which could phenocopy changes in Habp2 mRNA in response to TGF-beta, was found to be located in the 177-bp region upstream of the transcription start site, and this region did not contain any SMAD binding sites. PMID: 27462075
  15. Results show that G534E germline variant in HABP2 does not account for the familial nature of nonmedullary thyroid cancer in Australian kindreds but and is common in the general population. PMID: 27530615
  16. omology modeling suggested that the Glu-221 side chain could sterically hinder insertion of the N terminus into the HABP2 protease domain, helping to explain the detrimental effects of Glu-221 substitution on HABP2 activity. PMID: 28246168
  17. The data do not support the pathogenicity of the HABP2 c.1601G > A variant but highlight the existence of a new one that should be more extensively searched for in familial papillary thyroid carcinoma patients and its pathogenicity more carefully evaluated. PMID: 28089742
  18. No evidence supporting a role for the HABP2 G534E variant (SNP rs7080536) in papillary thyroid carcinoma. PMID: 26745718
  19. HABP2 G534E appears to be a susceptibility gene in a subgroup of Familial Non-Medullary Thyroid Cancer (FNMTC), providing important diagnostic implications for this hereditary thyroid cancer. PMID: 26832773
  20. HABP2, which encodes an extracellular serine protease involved in coagulation, fibrinolysis, and inflammatory pathways, may be a genetic susceptibility locus for early-onset stroke. [Meta-Analysis] PMID: 26732560
  21. Patients with Gram-negative sepsis caused by B. pseudomallei have abundant FSAP activation, which significantly correlates with stage of disease. PMID: 25370187
  22. results suggest that the HABP2 G534E variant is a susceptibility gene for familial nonmedullary thyroid cancer PMID: 26222560
  23. CD44 expression in squamous cell carcinoma of the penis cannot predict the need of performing inguinal lymphadenectomy. PMID: 25847894
  24. FSAP functions in initiation and progression of hepatic fibrosis PMID: 24497464
  25. The possible effects of omega-3 FA on clinical AF potential could be linked with modulation of circulating FSAP levels. PMID: 23575879
  26. FSAP activates the NF-kappaB pathway and the associated downstream pro-inflammatory factors in monocytic cells PMID: 24075769
  27. The study demonstrated that a single nucleotide polymorphism (Marburg I) in the FSAP gene (HABP-2)results in a weak proteolytic activity against all substrates including FVII. PMID: 22906531
  28. Lower FSAP expression is associated with enhanced liver fibrosis and inflammation in patients with chronic hepatic disorders and murine experimental liver injury. PMID: 22989567
  29. Data indicate that FSAP mediates proteolytic cleavage and activation of bone morphogenetic protein-2 (BMP-2). PMID: 23341458
  30. High levels of FSAP activity were predictive of adverse events during follow-up, suggesting its potential role in risk stratification and clinical management of CAD patients. PMID: 22850287
  31. We conclude that FSAP Marburg-I genotyping may be used to determine the risk for thromboembolic disorders in patients with suspected thrombophilia and known DVT or PE. PMID: 22421107
  32. Report tissue factor pathway inhibitor as an efficient inhibitor of factor VII-activating protease. PMID: 22449009
  33. Increased plasma FSAP antigen levels and activity were associated with ischemic stroke and all main etiologic subtypes. PMID: 22409238
  34. These results indicate that polymorphisms in the regulatory region of HABP2 gene could influence gene expression levels in the receptive endometrium and be one reason for infertility complications in women with unexplained infertility. PMID: 21098215
  35. Data suggest that plasma FSAP activity levels were higher in women with recurrent pregnancy loss than in fertile women. PMID: 22383781
  36. A high correlation between FSAP activity and C5a was found in multiple trauma patients PMID: 22308306
  37. Factor VII-activating protease promotes the proteolysis and inhibition of tissue factor pathway inhibitor. PMID: 22116096
  38. SNP analyses indicate an important role for FSAP in the regulation of the haemostasis system as well as fibroproliferative inflammatory processes. [review] PMID: 21655671
  39. these results suggest pathophysiological relevance of histone-dependent pro-PHBP activation in hyperinflammatory process. PMID: 21600885
  40. Marburg I polymorphism of FSAP might not be associated with cerebral infarction. PMID: 20045910
  41. identified laccaic acid as a potent inhibitor of the protease in terms of both autoactivation of the PHBP proenzyme (IC(50) = 0.35-0.55 microg/ml) and the catalytic activity of the active enzyme (IC(50) = 1.1 microg/ml). PMID: 21071862
  42. FSAP inhibited platelet-derived growth factor-stimulated proliferation, migration, p42/p44 MAPK phosphorylation and collagen III synthesis of the human pulmonary fibroblasts. PMID: 20818495
  43. The protein products HABP2 and HYAL1 were associated with plasma PAI-1 concentration and play key roles in hyaluronan metabolism, providing genetic evidence to link these pathways. PMID: 20558613
  44. Report that polyamine induces the formation of pro-PHBP autoactivation complex, in which an intermolecular interaction between N-terminal region and the third EGF-like domain (E3) plays a role. PMID: 19817990
  45. Hyaluronic acid binding protein 2 (HABP2) negatively regulates vascular integrity via activation of protease-activated receptor/RhoA/Rho kinase signaling. It represents a potential therapeutic target for syndromes of increased vascular permeability. PMID: 20042707
  46. The frequency of factor VII-activating protease Marburg I is significantly increased in patients with a history of venous thromboembolism (VTE) or idiopathic VTE compared to healthy controls. PMID: 15486068
  47. An interactive effect upon risk was found between the 511E allele and elevated levels of cholesterol and triglyceride or fibrinogen. The findings support the proposal that the FSAP 511E allele exacerbates atherosclerosis or its clinical sequelae PMID: 15543324
  48. extracellular RNA, present at sites of cell damage or vascular injury, can serve an important as yet unrecognized cofactor function in haemostasis by inducing (auto-)activation of FSAP through a novel surface-dependent mechanism PMID: 15654766
  49. Marburg I polymorphism of factor VII-activating protease does not have a role in venous thrombosis [letter] PMID: 15933067
  50. exhibits a significant growth factor-like activity on quiescent human lung and dermal fibroblasts PMID: 16153533

Show More

Hide All

Involvement in disease
Thyroid cancer, non-medullary, 5 (NMTC5)
Subcellular Location
Secreted. Note=Secreted as an inactive single-chain precursor and is then activated to a heterodimeric form.
Protein Families
Peptidase S1 family
Tissue Specificity
Ubiquitously expressed.
Database Links

HGNC: 4798

OMIM: 603924

KEGG: hsa:3026

STRING: 9606.ENSP00000277903

UniGene: Hs.422542

Call us
301-363-4651 (Available 9 a.m. to 5 p.m. CST from Monday to Friday)
7505 Fannin St., Ste 610, Room 322 (CUBIO Innovation Center), Houston, TX 77054, USA
Join Us with

Subscribe newsletter

Leave a message

* To protect against spam, please pass the CAPTCHA test below.
CAPTCHA verification
© 2007-2023 CUSABIO TECHNOLOGY LLC All rights reserved. 鄂ICP备15011166号-1